Recommendations for Clinical Trial Development in Mantle Cell Lymphoma
Stephen E. Spurgeon(Oregon Health & Science University), Mitchell R. Smith, Lawrence Baizer(Hackensack University Medical Center), John P. Leonard(New York University), Brian G. Till(University of Washington), Jonathan W. Friedberg(University of Rochester), Peter Martin(Northwestern University), Michael LeBlanc(Fred Hutch Cancer Center), Richard F. Little(Dana-Farber Cancer Institute), Brad S. Kahl(UW Health University Hospital), André Goy(Hackensack University Medical Center), Martin Dreyling(LMU Klinikum), Ajay K. Gopal(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 13
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma
|New England Journal of Medicine|2020|1.9k